AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The podcast highlights the significance of peripheral blood minimal residual disease (MRD) in myeloma treatment. Mass spectrometry is projected to emerge as a prevailing diagnostic tool, offering high sensitivity in peripheral blood testing. It can accurately predict long-term outcomes and guide therapy adjustments. Additionally, the session discusses the utility of whole genome scanning, although its sensitivity is anticipated to be inferior to mass spectrometry. Furthermore, it explores the potential of antibody therapy and amyloidosis treatment through distinguishing tumor clones from regenerating clones and exploring novel protein forms.